Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...

Looking for value in crypto without breaking the bank? This guide dives into BlockDAG, Ethena, Hedera, and Stellar, which are ...

Humanitarian aid organizations and international bodies have warned that Gaza is facing "critical" levels of hunger and that ...

Starbucks will close all 'Pick Up' stores by 2025 to focus on traditional cafés and rebuild customer connection.

July was a roller coaster for New York City FC. In Major League Soccer, the team won two road games while going 3-1-1, ...

This opportunity has now been extended through December 31, 2025, with $713,405 remaining thanks to an individual gift match ...

Owing to Briumvi's solid launch, TG's balance sheet is in excellent condition. Despite new competition, Briumvi's five-year ...

The bad news keeps on creeping toward Vyne Therapeutics’ BET inhibitor platform. | Weeks after the biotech gave up on a ...

Using a technique known as “thermal quenching,” scientists made a quantum material that can switch instantly between ...

Florida's special teams unit has a ton of experience under its belt. Coordinator Joe Houston broke down his unit ahead of ...

Inter Miami and Atlas meet for the first time in Leagues Cup play - see how both teams are trending and what to expect from ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s cobolimab has ...